# HugoScore CAIHL Draft Report: InstaDoc

Status: Draft for human review
Last reviewed: 2026-07-30
Review method: Deep public-source review of the live InstaDoc homepage, pre-consent symptom-checker flow, pricing, privacy, terms, editorial, citations, medical-team, and state-availability pages; Panagea Medical Group's About, privacy, patient-consent, and workflow pages; current FDA and HHS guidance; credible launch coverage; and searches for independent evaluation. No completed assessment, real patient data, account, payment, prescription, clinician interaction, security/accessibility audit, legal review, regulatory determination, or independent validation.
Service: InstaDoc
Vendor: InstaDoc, LLC; clinical services are described as provided by Panagea Medical Group, PC
URL: https://instadoc.health/
Category: AI-enabled virtual primary care

## 1. Executive Summary

InstaDoc is a direct-to-consumer AI symptom assessment and asynchronous telemedicine service. Patients can start a free, no-account symptom checker and, where available, request prescriptions, sick notes, or specialist referral letters from clinicians working through Panagea Medical Group.

Under CAIHL, InstaDoc is strongly patient-directed: the patient chooses the tool, defines the problem, can stop before accepting the terms, and selects the pharmacy. It could expand agency by helping people organize symptoms, understand possible next steps, and access low-cost care.

The public record also contains material contradictions:

- The homepage markets “common urgent care services,” while the terms say not to use the service for “urgent care needs.”
- Public pages say assessments are reviewed by licensed professionals, while the terms require independent verification by a board-certified physician before a patient relies on any AI output; nurse-practitioner or physician-assistant review does not satisfy that requirement.
- The homepage displays prescriptions and referrals from $1 and a $5 sick note, while the pricing page lists prescriptions from $15 and notes from $14.99.
- Panagea's public pages label the DoseSpot/e-prescribing integration “certification pending,” while InstaDoc markets prescriptions sent to the patient's pharmacy.
- The AI model/provider and full model-data path are not disclosed.
- The state-availability page does not list states.
- No independent clinical validation, published benchmark, subgroup analysis, or outcome study was found.

**Agency posture:** Potentially agency-expanding, with clinical-governance, verification, and disclosure contradictions

**Agency axis position:** 82 of 100

**Confidence:** Low-to-medium draft, official live-product and policy review plus limited launch reporting; no independent validation

The agency axis reflects who chooses and controls the tool. It is not a safety, accuracy, privacy, quality, or clinical-effectiveness score.

## 2. CAIHL Question

**Who does InstaDoc serve?**

InstaDoc primarily serves patients seeking immediate, low-cost symptom guidance and a pathway to asynchronous care. It also serves InstaDoc and Panagea's commercial interests: the free assessment can lead to paid services from a medical group that the companies say is legally separate but shares a common founder.

- **Classification:** Patient-directed, vendor-hosted AI symptom assessment with affiliated asynchronous clinical care.
- **Primary user:** U.S. adults seeking symptom guidance, prescriptions, notes, or referrals.
- **Hosting/control:** InstaDoc controls the AI intake and software; Panagea controls clinical decisions; patients control entry, submitted information, paid escalation, and pharmacy choice.
- **Interest alignment:** Patient access and navigation, with vendor and affiliated-medical-group interests.

## 3. What the Service Does

Public materials describe:

- A free AI symptom checker asking age, sex assigned at birth, duration, symptoms, and follow-up questions.
- Possible-condition, testing, treatment, and next-step guidance.
- A “Tough Case Solver” for chronic or uncommon symptoms.
- Asynchronous clinician review for prescription, sick-note, and referral requests.
- Prescriptions for selected uncomplicated conditions and medication refills.
- Secure messaging, a patient portal, patient-selected pharmacies, and e-prescribing.
- Published clinical-record access, export, amendment, disclosure-accounting, restriction, and authorization-revocation rights through Panagea.

InstaDoc says it is a software company, not a medical practice. Panagea says it supplies clinical care and shares a founder with InstaDoc.

## 4. Patient-Impact Pathway

1. A patient voluntarily selects a free assessment or care pathway.
2. The patient supplies demographics, symptoms, history, and follow-up answers.
3. InstaDoc's AI and software generate questions, summaries, and possible next steps.
4. The patient receives informational output or sends the intake to an affiliated medical group.
5. A Panagea clinician licensed in the patient's state may review the case and AI suggestions.
6. The clinician may accept, change, or reject the suggested care and may issue a prescription, note, or referral.
7. The patient selects a pharmacy; public pages currently describe the e-prescribing integration as certification pending.
8. Clinical-record correction routes are published, but a direct correction or appeal route for the free AI assessment was not found.

## 5. Evidence Table

| Source | Main finding | Evidence limits |
| --- | --- | --- |
| https://instadoc.health/ | Live services, AI visibility, prices, urgent-care framing, clinician-review language, and patient-facing claims. | Vendor marketing; copy and pricing conflict with other pages. |
| https://instadoc.health/pricing | Free assessment, prescriptions from $15, notes from $14.99, and no subscription. | Conflicts with homepage prices. |
| https://instadoc.health/privacy | Anonymous-intake claim, no sale/ad sharing/AI training, limited analytics, and access/deletion rights. | No AI provider, model path, detailed security, or retention schedule. |
| https://instadoc.health/terms | Software/provider split, AI fallibility, board-certified-physician verification requirement, urgent-care exclusion, data uses, and liability terms. | Legal terms, not proof of operation; several provisions conflict with product framing. |
| https://instadoc.health/editorial-policy | AI-assisted content and clinician-review process. | Applies to published content, not proof of interactive assessment accuracy. |
| https://instadoc.health/citations | Lists preferred government, professional-society, and literature sources. | Does not show how any specific output retrieves or applies evidence. |
| https://instadoc.health/medical-team | Panagea relationship, common founder, and clinician-review claims. | Vendor-authored; public clinician roster and review metrics are limited. |
| https://instadoc.health/states | State availability is being updated. | No current state list. |
| https://panagea.health/about | Platform/medical-group split, named founder, limitations, and e-prescribing status. | Panagea-authored; certification is described as pending. |
| https://panagea.health/how-it-works | Clinician review, independent prescribing, patient pharmacy choice, and controlled-substance block. | Intended workflow; not independently audited. |
| https://panagea.health/privacy | Clinical data categories, named processors, HIPAA rights, no sale/training, and retention posture. | AI provider absent; retention not quantified. |
| https://panagea.health/terms | Active consent, asynchronous-care risks, secure messaging, PHI uses, and e-prescribing consent. | Public consent text; no completed encounter reviewed. |
| https://www.wmbfnews.com/2026/07/02/myrtle-beach-doctor-launches-ai-powered-medical-guidance-website/ | Launch coverage and founder claims about access, pricing, and benchmarking. | No benchmark methods or independent testing. |
| https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software | Current function-specific CDS guidance, including patient/caregiver software. | General guidance; HugoScore makes no product determination. |
| https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html | General covered-entity and business-associate requirements. | No legal conclusion about InstaDoc's processing stages. |

## 6. Mixed HugoScore Profile

| Public question | Answer | Rationale |
| --- | --- | --- |
| Who does this AI serve? | Patients directly, with vendor and affiliated-medical-group interests | Patients choose the problem and tool; free guidance also creates a paid-care funnel. |
| Can patients tell AI is involved? | Yes | AI is named before use and throughout public pages and terms. |
| Can patients meaningfully choose? | Partial to yes | Use is voluntary and no-account entry is available, but state coverage, prices, and paid escalation are inconsistent or incomplete. |
| Can patients correct or challenge what the AI produces? | Partial | Panagea publishes messaging and record-amendment rights; no direct correction, model-provenance, or output-appeal workflow for the free assessment was found. |
| Does it help patients understand or act? | Potentially yes | Symptom reflection, next steps, prescriptions, notes, and referrals are action-oriented, but outcomes and safety are not independently validated. |

### Equity Burden

Low-cost, no-waiting-room access could reduce financial, travel, and gatekeeping burdens. The service is also U.S.-only, 18+, English-first, internet-dependent, and based on typed self-report without a physical exam. State availability, accessibility, language support, low-literacy testing, caregiver/proxy controls, and subgroup performance are not disclosed. The terms' requirement for independent board-certified-physician verification places a large burden on people using the service because ordinary access is already difficult.

### Data Governance

InstaDoc says the free intake remains anonymous until the patient sends it to a medical entity, and says it does not sell health data, share it with advertisers, or use it to train AI models. Panagea lists Supabase, DoseSpot, Stripe, Twilio, Resend, and IDScan and publishes record access, export, amendment, disclosure-accounting, restriction, and revocation rights.

The AI model/provider, inference location, prompt/output logging, anonymous-session retention, quantified clinical retention, de-identification method, and full business-associate path are not disclosed.

### Clinical Boundaries

Emergency exclusions, AI fallibility, clinician authority, asynchronous-care risks, and controlled-substance limits are public. The boundary is not coherent across pages: urgent-care marketing conflicts with an urgent-care prohibition; licensed-professional review conflicts with a board-certified-physician verification condition; and prescription promises coexist with a pending e-prescribing certification statement.

FDA's current approach is function-specific. This draft makes no regulatory determination.

### Evaluation Ownership

Evaluation is vendor- and clinician-founder-defined. The citations hub and editorial policy are useful, but no public patient-partnered evaluation, reproducible benchmark, independent clinical validation, prospective outcome study, subgroup analysis, accessibility audit, or security audit was found.

## 7. Key Unknowns

- AI model/provider, routing, prompts, inference location, retention, and quality-assurance use.
- Whether a clinician reviews each free assessment or only the underlying protocols.
- How users can satisfy the board-certified-physician verification requirement.
- Current state availability and clinician coverage.
- Current prices and wait-time tiers.
- Current e-prescribing certification and live transmission status.
- Validation methods, error cases, triage sensitivity, calibration, subgroup performance, and patient outcomes.
- Direct correction, human-review, and incident-escalation routes for free AI output.
- Anonymous-session retention and linkage risk.
- Security assurance, accessibility, and complete subprocessor disclosure.
- Commercial relationship and incentives between InstaDoc and Panagea.
- Function-specific regulatory posture.

## 8. Patient Agency Interpretation

InstaDoc begins from a patient-defined problem and may provide practical leverage: organizing symptoms, identifying tests or specialists to discuss, and reaching low-cost care.

Agency requires coherent disclosure. Patients cannot calibrate trust if “urgent care,” “clinician reviewed,” “from $1,” “outside partner,” “private,” and “prescription ready” mean different things across pages. The independent-verification clause is especially important because it transfers a difficult safety task back to the patient.

A more agency-supportive service would publish one consistent scope, price, and state list; identify the AI and data path; say exactly when a named clinician reviews an output; resolve the e-prescribing wording; add citations, visible uncertainty, correction, and human review to every assessment; and publish independent safety, equity, and outcome evidence.

## 9. Publication Recommendation

Publish as a low-to-medium-confidence AI-assisted public-source draft under AI-enabled virtual primary care. Do not mark reviewed or verified, and do not describe InstaDoc as safe, accurate, clinically effective, or regulatorily cleared.

Human review should prioritize urgent-care scope, clinician-review claims, the board-certified-physician verification requirement, live e-prescribing status, state availability, pricing, AI/model disclosure, retention, correction rights, and independent validation.

## Review Provenance

- Criteria: HugoScore patient agency framework derived from CAIHL, using the same public questions and mixed answer types applied to every tool.
- Submission: Brought to HugoScore through a screenshot of founder Jon Pangia's public LinkedIn profile on 2026-07-30; the screenshot was treated only as a lead.
- Reviewer: AI-assisted public-source draft prepared in OpenAI Codex; no named human reviewer is recorded.
- AI / model: OpenAI Codex / GPT-5-based assistant.
- Human review: No comprehensive human review has been completed or claimed.
- Review date: 2026-07-30.
- Limitations: No completed symptom assessment, real patient data, account, identity verification, payment, prescription, note, referral, clinician interaction, source-code inspection, vendor interview, security/accessibility audit, legal review, regulatory determination, or independent clinical validation.